Cited 0 times in Scipus Cited Count

Clinical and Laboratory Factors Associated with Symptom Development in Asymptomatic COVID-19 Patients at the Time of Diagnosis

DC Field Value Language
dc.contributor.authorOh, HS-
dc.contributor.authorKim, JH-
dc.contributor.authorWoo, ML-
dc.contributor.authorKim, JY-
dc.contributor.authorPark, CH-
dc.contributor.authorWon, H-
dc.contributor.authorLim, S-
dc.contributor.authorJeong, H-
dc.contributor.authorHam, SY-
dc.contributor.authorKim, EJ-
dc.contributor.authorSheen, S-
dc.contributor.authorKang, YM-
dc.contributor.authorYoon, D-
dc.contributor.authorLee, SY-
dc.contributor.authorSong, KH-
dc.date.accessioned2022-12-26T00:39:17Z-
dc.date.available2022-12-26T00:39:17Z-
dc.date.issued2021-
dc.identifier.issn2093-2340-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23528-
dc.description.abstractIn preparation for the surge of coronavirus disease 2019 (COVID-19), it is crucial to allocate medical resources efficiently for distinguishing people who remain asymptomatic until the end of the disease. Between January 27, 2020, and April 21, 2020, 517 COVID-19 cases from 13 healthcare facilities in Gyeonggi province, Korea, were identified out of which the epidemiologic and clinical information of 66 asymptomatic patients at the time of diagnosis were analyzed retrospectively. An exposure-diagnosis interval within 7 days and abnormal aspartate aminotransferase levels were identified as characteristic symptom development in asymptomatic COVID-19 patients. If asymptomatic patients without these characteristics at the time of diagnosis could be differentiated early, more medical resources could be secured for mild or moderate cases in this COVID-19 surge.-
dc.language.isoen-
dc.titleClinical and Laboratory Factors Associated with Symptom Development in Asymptomatic COVID-19 Patients at the Time of Diagnosis-
dc.typeArticle-
dc.identifier.pmid34951530-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731255/-
dc.subject.keywordAsymptomatic-
dc.subject.keywordCOVID-19-
dc.subject.keywordMedical resource allocation-
dc.subject.keywordSARS-CoV-2-
dc.subject.keywordSymptom development-
dc.contributor.affiliatedAuthorKim, EJ-
dc.contributor.affiliatedAuthorSheen, S-
dc.type.localJournal Papers-
dc.identifier.doi10.3947/ic.2021.0077-
dc.citation.titleInfection & chemotherapy-
dc.citation.volume53-
dc.citation.number4-
dc.citation.date2021-
dc.citation.startPage786-
dc.citation.endPage791-
dc.identifier.bibliographicCitationInfection & chemotherapy, 53(4). : 786-791, 2021-
dc.identifier.eissn2092-6448-
dc.relation.journalidJ020932340-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Infectious Diseases
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Files in This Item:
34951530.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse